Teva offer to buy Mylan from Natco

Natco Pharma had challenged Israel based Teva Pharmaceutical's patented 20 mg dosage version of Copaxone in US courts.
The agreement between Natco and Mylan states the two would collaborate to market and distribute Copaxone worldwide

Pharmaceutical's patent on Copaxone, which accounts for 50 percent of its profits through sales of USD 4 billion a year, is due to expire in September.

Thus, Teva made an offer to buy out Mylan for 40 billion USD.


Lets keep a watch on Natco.

Update 28th April -
Natco has rejected the offer from Teva. Stock surged 11%]

Pradhan Mantri Suraksha Bima Yojana (PMSBY) and Pradhan Mantri Jeevan Jyoti Bima Yojana (PMJJBY)

Come June and you may have an additional insurance option backed by the Govt.

• Pradhan Mantri Suraksha Bima Yojana (PMSBY)
• Pradhan Mantri Jeevan Jyoti Bima Yojana (PMJJBY)

Some details:

Pradhan Mantri Suraksha Bima Yojana (PMSBY)

• Eligibility - 18 - 70 yrs (need bank account)
• Premium - 12 Rs per annum
• Risk cover - 2L (for death or permanent disability) and 1L (for partial disability)
• Term - pay per year to renew
• Scheme premium comes under section 80C
• Amount also comes under tax exemption (< 1L), else TDS of 2% (if no Form 15H/G is given)

Pradhan Mantri Jeevan Jyoti Bima Yojana (PMJJBY)

• Eligibility - 18 - 50 yrs (need bank account)
• Premium - 330 Rs per annum
• Risk cover - 2L (death)
• Term - pay per year to renew

More details soon.

OIL,ONGC - Need not pay for the LPG subsidy for the current fiscal

So, there has been an announcement that OIL and ONGC will not have to pay subsidy for the current fiscal for LPG. The Govt will take care of it.

After diesel was deregulated in October 2014, the subsidy sharing was limited to LPG and kerosene.

They will be paying for the kerosene though.

So what do they do with this cash?
Pay dividends? No...the Govt expects them to invest aggressively in exploration...good thought.

A positive news for these companies.

Will it go into your buy radar?

Daiichi Sankyo sells stake in Sun Pharma

Sun Pharma shares crashed 11% early in trade today following the news that Daiichi Sankyo had sold its stake between 930-968 Rs per share.

Daiichi Sankyo sold 8.9% stake.

It had obtained the stake following the merger of Ranbaxy with Sun Pharma.

The merger with Ranbaxy has fortified Sun Pharma's position as the world's fifth largest specialty generic pharma firm.

The merger with Ranbaxy has fortified Sun Pharma's position as the world's fifth largest specialty generic pharma firm and the top-ranking domestic one with a significant lead in the market share.

Read more at: http://www.moneycontrol.com/news/buzzing-stocks/sun-pharma-plunges-11-as-daiichi-sankyo-offloads-stake_1363247.html?utm_source=ref_article

The merger with Ranbaxy has fortified Sun Pharma's position as the world's fifth largest specialty generic pharma firm and the top-ranking domestic one with a significant lead in the market share.

Read more at: http://www.moneycontrol.com/news/buzzing-stocks/sun-pharma-plunges-11-as-daiichi-sankyo-offloads-stake_1363247.html?utm_source=ref_article

The merger with Ranbaxy has fortified Sun Pharma's position as the world's fifth largest specialty generic pharma firm and the top-ranking domestic one with a significant lead in the market share.

Read more at: http://www.moneycontrol.com/news/buzzing-stocks/sun-pharma-plunges-11-as-daiichi-sankyo-offloads-stake_1363247.html?utm_source=ref_article

The merger with Ranbaxy has fortified Sun Pharma's position as the world's fifth largest specialty generic pharma firm and the top-ranking domestic one with a significant lead in the market share.

Read more at: http://www.moneycontrol.com/news/buzzing-stocks/sun-pharma-plunges-11-as-daiichi-sankyo-offloads-stake_1363247.html?utm_source=ref_article

Daiichi Sankyo

Read more at: http://www.moneycontrol.com/news/buzzing-stocks/sun-pharma-plunges-11-as-daiichi-sankyo-offloads-stake_1363247.html?utm_source=ref_article

Daiichi Sankyo

Read more at: http://www.moneycontrol.com/news/buzzing-stocks/sun-pharma-plunges-11-as-daiichi-sankyo-offloads-stake_1363247.html?utm_source=ref_article

Daiichi Sankyo

Read more at: http://www.moneycontrol.com/news/buzzing-stocks/sun-pharma-plunges-11-as-daiichi-sankyo-offloads-stake_1363247.html?utm_source=ref_article

Reliance Industries - good results.

On 17th April 2015, Reliance Industries came out with strong quarterly results.

The company's consolidated net profit rose to a seven-year high of Rs 6,381 crore against a net profit of Rs 5921 crore in the previous quarter.

Q4 GRMs grew at $10.1 per barrel vs $7.3 per barrel.

Outstanding debt as on March 2015 was Rs 1.6 lakh crore compared to Rs 1.38 lakh crore at the end of previous financial year.

Cash and cash equivalents were at Rs 84,472 crore as of March 2015.

Dividend of 10 Rs per share was declared.

However, RIL share price opened little higher today (20th April) @ 937 INR. At the time of writing the article, it was trading at -0.41% lower at 922 INR.

One needs to note that if one sees the price band of 850-920 INR, while the sensex has zoomed, reliance hasn't delivered the returns that the investors were hoping from it.

Will Mukesh Ambani be able to redeem the faith that many investors have on him?
Only time will tell.

Govt divesting stake in BEL and NBCC and other PSU's

Govt is looking to divest its stake in some PSU's.
NBCC and BEL (Bharat electronics) in the list will have some investors interested.


Both of these PSU's have run up a lot. Its not without any reason.

NBCC would be the first choice for the following two reasons:
Govt thrust on Make in India
Govt planning to infuse funds in PSU banks (which should go to NBCC for its projects).

BEL has run up a lot from 900 to 3K and now has an order of 50K crore for defence.
This is another beneficiary of the Govt's thrust on defence.

Would be interesting to track these two.

Ace investor Vijay Kedia had named these two stocks as part of his "keep for 5 years" portfolio.
Have a look here:
http://mymoneyrules.blogspot.in/2015/04/thoughts-from-ace-investor-vijay-kedia.html

Am I invested? Not at the moment. Keeping track.
Is this a recommendation to invest? Not at all. I am not registered at SEBI and am not recommending these for investment.

Thoughts from Ace Investor Vijay Kedia

Ace value investor Vijay Kedia made the following observations in an interview recently.

As per him, market rewards one as per his/her perception of the market.
If one assumes the market to be a gambling den...then it will prove a casino for him/her.
In a casino, the house always wins. In this case, assume the house to be brokerages, tax authorities etc

If one is in the market for day trading (to earn a livelihood)
Daily trading is a full time job.
Its the hardest place to make easiest money in the world.
No part time fun.

If one considers the market to be another avenue for investment, then this is market for you.
One needs to remember that Rome was not built in a day. We need to give time to our investments to grow.
Give it time to mature.
Market is volatile and there are risks. Stay invested with conviction.

He also advocated to buy simple story stocks and not go for complex story with an interesting example on human psychology.

When one gets hurt, people apply dettol. Very few go for Savlon.
That's because dettol has a different smell and it burns. When it burns, people think its healing the wound.
People thus go for complex stories which they assume on their own.

Current stocks that he is banking on?

• Cera Sanitaryware
• Aries Agro (micro nutrient story in long term)
• BEL (defence)
• NBCC
• RCF
• Sudarshan Chemicals
• Repro (digitization of text books in the long term)

What do you think?

The interview can be heard here:
economictimes.indiatimes.com/et-now/experts/market-makers-with-vijay-kedia-kedia-securities/videoshow/46947924.cms